Semler Scientific Reports Mixed Q3 Results Focused on Bitcoin

image

Semler Scientific Reports Mixed Q3 Results Focused on Bitcoin

Semler Scientific Inc. (SMLR), a company specializing in medical technology and services, reported mixed financial results for the third quarter of 2024. While the company experienced a decline in revenues, operating income remained strong. The focus during the call was on an aggressive Bitcoin treasury strategy involving the purchase of Bitcoin as a primary reserve asset.

Despite lower revenues, the company gained from changes in the fair value of its Bitcoin assets. Semler Scientific continues to innovate in its core medical product lineup, focusing on its flagship product, the QuantaFlo device, which aids in the early diagnosis of peripheral artery disease (PAD).

Key Points:

  • Q3 2024 revenues decreased by 17% year-over-year to $13.5 million.
  • Operating income remained robust at $5.1 million.
  • Semler Scientific utilized most of its cash to buy Bitcoin and owned 1,058 Bitcoins as of November 5, 2024.
  • The company is exploring additional financing options to further increase its Bitcoin holdings.
  • Semler aims to obtain a new 510(k) approval for an extension of the QuantaFlo product, expected to take place in the first half of 2025.

Company Outlook:

  • Semler Scientific expects its fourth quarter revenues to follow a similar trend as the previous year.
  • The company continues to focus on tight cost controls.
  • Semler's long-term vision includes reaching additional cardiovascular applications.

Negative Aspects:

  • A significant 17% revenue drop compared to Q3 2023.
  • Two customers accounted for a large portion of quarterly revenues, indicating potential concentration risks.

Positive Aspects:

  • The company's Bitcoin treasury strategy is viewed as a contributor to equity.
  • Confidence in Bitcoin's investment potential remains high.
  • Semler benefits from strong operational cash flow and a market offering program supporting Bitcoin purchases.

Shortcomings:

  • Despite strong operating income, the decline in revenue may raise concerns about the growth trajectory of the company's core business.

Q&A Highlights:

  • Semler Scientific is considering issuing debt or convertible bonds to finance additional Bitcoin purchases.
  • The company currently does not meet the public stock requirements for an options listing, but may meet those in the future as it increases the number of shares outstanding through its ATM program.
  • Demand for QuantaFlo software licenses continues alongside market expansion into new customer segments.
  • Semler Scientific focuses on maximizing operating income while allocating excess cash to Bitcoin investments.
  • The company monitors Bitcoin returns as a significant performance metric and may include it in future press releases.

Semler Scientific's Q3 earnings call highlighted a noteworthy decline in revenues but strong operating income. The company’s strategic emphasis on accumulating Bitcoin as a treasury reserve asset was evident through substantial investments made via operational cash flow and equity offerings.

While the company’s core medical products and services business, particularly the QuantaFlo device, remains a priority, the aggressive Bitcoin strategy and investigations into additional financing for further Bitcoin purchases indicate a dual focus. The company's efforts to obtain a new 510(k) approval for QuantaFlo reflect its ongoing commitment to medical innovation.

As Semler Scientific manages the balance between its medical technology operations and Bitcoin investment strategy, stakeholders will closely monitor how these dual priorities evolve in the upcoming quarters.

InvestingPro Forecasts: Semler Scientific's mixed Q3 results and bold Bitcoin strategy are reflected in several key metrics and forecasts derived from InvestingPro. Despite the reported revenue decline, the company maintains impressive gross profit margins; InvestingPro data shows an 88.67% gross profit margin for the trailing twelve months as of Q2 2024. This aligns with the company's ability to achieve strong operating income despite falling revenues.

One InvestingPro insight highlights that management is aggressively repurchasing shares, which could be seen as a sign of confidence in the company’s future, including its Bitcoin strategy. This is consistent with Semler's focus on maximizing shareholder value through both its core operations and cryptocurrency investments.

Another InvestingPro tip underscores that the company’s valuation implies strong free cash flow returns. This might explain Semler's ability to allocate significant resources to Bitcoin purchases while maintaining operational efficiency. With a price-to-earnings (P/E) ratio of 12.94, the company appears reasonably valued, particularly considering its innovative approach to treasury management.

It is worth noting that analysts forecast a decline in sales for the current year, which is consistent with the reported Q3 results. However, the company's recent strong returns (19.93%) may indicate that investors have responded positively to Semler's Bitcoin strategy and overall business outlook.

For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional insights that provide a deeper understanding of Semler Scientific's financial health and market position.